Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial
Top Cited Papers
- 1 March 2006
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 367 (9513), 825-831
- https://doi.org/10.1016/s0140-6736(06)68338-4
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myelomaCancer, 2005
- Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myelomaBlood, 2005
- Cancer and venous thromboembolismThe Lancet Oncology, 2005
- Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myelomaThe Hematology Journal, 2004
- Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone(T-VAD doxil): a phase II multicenter studyAnnals of Oncology, 2004
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical PatientsNew England Journal of Medicine, 1999
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958